For companies and non-profits
Are you interested in setting up a Research & Development collaboration with one of the Amsterdam universities or medical centers? Access new knowledge. As a knowledge transfer office (KTO), IXA is your single point of contact for all Amsterdam academic and practice–based research. We act as an intermediary, connecting companies, non-profits, governments, health care institutions and educational institutions to the researchers and facilities of Amsterdam UMC, Amsterdam University of Applied Sciences (HvA), University of Amsterdam (UvA) and Vrije Universiteit Amsterdam (VU).
Please contact us if:
- you are looking for licensing opportunities
- you want to get in touch with a research expert in your organisations field
- you are looking for a solution to a specific R&D challenge
- you wish to access the universities’ research facilities and expertise
- you are keen to invest in a certain spin-off company
UvA spin-off Panel BV receives PoC funding from Innovatiefonds Noord-Holland (IFNH)
Panel B.V., a spin-off from the University of Amsterdam, has received a loan from the Innovatiefonds Noord-Holland. This loan will enable Panel to continue building its innovative tool for inclusive participation processes. The unique method was designed by sociologists Gerben Moerman and Christiaan Bröer of the UvA Faculty of Social and Behavioural Sciences. The method […]
News
Two VU start-ups in Techleap’s Pole Position programme
Photosynthetic & Veridis, two VU start-ups, are part of the Pole Position Programme #4 by Techleap. Through the programme, like-minded industry experts who will guide the founders of Photosynthetic & Veridis on their journey towards becoming global leaders and take Pole Position. Techleap is a government funded organization to connect and empower startups to grow and sustain a productive tech community.
News
Phlox Therapeutics raises additional seed funding for RNA therapies
Phlox, a private biotechnology spin-off from Amsterdam UMC and specializing in developing innovative RNA-therapeutics for rare genetic cardiomyopathies, has secured additional seed funding to advance Phlox’s lead program aimed at rare genetic laminopathies.
News